Illumina Shares Rated 'Hold' by Analysts

Eighteen brokerages provide average 'Hold' rating for the life sciences company's stock.

Apr. 20, 2026 at 8:56am

Got story updates? Submit your updates here. ›

A high-contrast black and white close-up of intricate, heavy industrial banking machinery and gears, representing the tangible financial infrastructure that underpins the life sciences industry.Illumina's genetic sequencing technology powers much of the modern life sciences industry, though the company faces a cautious outlook from Wall Street.San Diego Today

Shares of Illumina, Inc. (NASDAQ:ILMN) have received an average 'Hold' rating from eighteen research firms covering the stock, according to MarketBeat.com. The analysts' average 12-month price target for Illumina is $129.69.

Why it matters

Illumina is a leading provider of genetic sequencing technology used in research, clinical diagnostics, and consumer genomics. The 'Hold' rating from analysts suggests the stock may be fairly valued at current levels, with some uncertainty around the company's near-term growth prospects.

The details

The eighteen research firms covering Illumina stock have issued two 'Sell' ratings, ten 'Hold' ratings, and six 'Buy' ratings. Analysts have set an average 12-month price target of $129.69 for the stock. Recent price targets from individual firms range from $135 to $170 per share.

  • Illumina reported Q4 2025 earnings on February 5, 2026.

The players

Illumina, Inc.

A global life sciences company that develops, manufactures, and markets integrated systems for genetic analysis and sequencing.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The 'Hold' rating on Illumina stock suggests analysts see the company as fairly valued, with some uncertainty around its near-term growth prospects. This reflects the competitive landscape and regulatory environment facing the life sciences industry.